biologic

Heplisav-B

Hepatitis B Vaccine (Recombinant), Adjuvanted

Loss of exclusivityNovember 2029projected — 12-year biologic exclusivity estimate

CompanyDynavax Technologies Corporation

Drug detail

Brand name	Heplisav-B
Active ingredient	Hepatitis B Vaccine (Recombinant), Adjuvanted
Strength	20UG/.5ML
Dosage form	Injection
Route	Intramuscular
Modality	Biologic
FDA approval	November 2017
Marketing status	Rx

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.